Brought to you by 
Takeda buys Inviragen for $35mm plus up to $215mm in earn-outs
26 Aug 2020
Executive Summary
Takeda Pharmaceutical Co. Ltd. is continuing to grow its vaccines business, this time through the acquisition of Inviragen Inc., a privately owned biotech with projects in preclinical through Phase II trials for various infectious diseases. Takeda paid $35mm in cash up front, and could hand over up to an additional $215mm in development and commercialization earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda buys Inviragen for $35mm plus up to $215mm in earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice